InterVene’s BlueLeaf Endovenous Valve Formation (EVF) System Granted Breakthrough Device Designation by the FDA
December 13, 2021
InterVene has been granted Breakthrough Device Designation by the FDA for the BlueLeaf Endovenous Valve Formation System.
Safety and feasibility report on nonimplantable endovenous formation for the treatment of deep vein reflux.
January 19, 2021
First report of the one year follow up results of the BlueLeaf endovenous valve formation from the international feasibility study.
Early results of endovenous valve formation study confirm feasibility for treatment of deep vein reflux
March 6, 2020
A 12- month study conducted by Commonwealth physicians have demonstrated that endovenous valve formation in the deep venous system is feasible. Dr. Varcoe provided results for the first 14 patients treated at the annual meeting of the American Venous Forum (AVF).
InterVene, Inc. Wins TCT 2019 Shark Tank Innovation Competition
September 29, 2019
InterVene wins the Shark Tank Innovation Competition at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) Conference, a premier educational meeting focusing on interventional cardiovascular medicine.
InterVene Raises $15 Million in Series B Funding for First Catheter-Based System to Correct Deep Vein Valve Failure
June 25, 2019
InterVene Inc. has raised $15 million for its BlueLeaf® Endovenous Valve Formation System, the first catheter-based solution for deep vein reflux.
InterVene Raises $5.9 Million in Series A Funding to Correct Deep Vein Valve Insufficiency with Minimally Invasive Catheter Technology
March 23, 2015
InterVene announced the initial closing of $5.9MM in Series A funding for trials of its minimally invasive catheter therapy for deep vein valve insufficiency, creating new valves from the vein wall.